New Study: Why Ozempic Works Better for Some Due to Genetics

Ozempic genetic variants are emerging as a key factor in why the popular weight-loss drug semaglutide produces dramatically different results across patients. A groundbreaking study suggests that specific genetic differences influence how the body responds to Ozempic, explaining variations from no weight loss to 25% body weight reduction.

In one analysis, users reported an average loss of 10 percent of their body weight on these GLP-1 medications. Yet outcomes varied widely: some lost no weight, while others achieved 25 percent reductions. This new research from the 23andMe Research Institute points to genetics as one influential subcomponent among several factors affecting weight loss success with Ozempic.

The Study Behind Ozempic's Variable Effectiveness

The study, accompanied by a Nature article, was co-authored by Adam Auton, vice-president of human genetics at the 23andMe Research Institute—a non-profit organization that also offers DNA testing. "There's a number of factors that can influence weight loss, of which genetics is a subcomponent," Auton stated.

Researchers examined genes encoding receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—hormones mimicked by these drugs. Ozempic, a semaglutide injection, imitates GLP-1 to regulate appetite and metabolism. Tirzepatide, another common option, targets both GLP-1 and GIP receptors for potentially enhanced effects.

The sample size was significant, providing robust data on real-world responses. However, the genetic effects on weight loss were described as relatively small, prompting caution in clinical application.

How Ozempic and Tirzepatide Interact with the Body

GLP-1 receptor agonists like Ozempic work by mimicking the GLP-1 hormone, which is naturally released after eating. This slows gastric emptying, signals fullness to the brain, and improves insulin sensitivity, leading to reduced calorie intake and better blood sugar control. These mechanisms make Ozempic effective not just for type 2 diabetes but also for obesity management.

Tirzepatide builds on this by also activating GIP receptors, which further enhance insulin secretion and may promote fat metabolism. Understanding these pathways is crucial because genetic variants alter receptor encoding, directly impacting drug efficacy and tolerability.

Clinical Background: Why Genetic Differences Matter

Individual responses to pharmacotherapy have long puzzled clinicians. For GLP-1 drugs, factors like diet, exercise, and comorbidities play roles, but genetics add a personalized layer. This study highlights how variations in receptor genes can predict better or worse outcomes, paving the way for precision medicine in metabolic health.

Genetic Variants Linked to Greater Weight Loss

Researchers identified a specific variant in the gene encoding GLP-1 receptors. Patients with one copy of this variant lost 0.76 kilograms more than those without it when using weight-loss drugs like Ozempic. Those with two copies fared even better, losing nearly twice as much: 1.5 kilograms more.

These findings quantify how genetics can tip the scales—literally—in favor of enhanced weight loss for a subset of users. While the absolute differences are modest, they compound over time, especially when combined with lifestyle changes.

Genetics and Side Effects: Nausea, Vomiting Risks

Not all genetic news is positive. Two variants in GLP-1 encoding genes were associated with heightened side effects. One raised the risk of nausea by more than 57 percent, while another increased vomiting risk by 36 percent.

For tirzepatide users, a GIP-encoding variant made patients 83 percent more likely to experience vomiting. Gastrointestinal issues like these are common with GLP-1/GIP agonists, often improving over time, but genetic predispositions could help identify at-risk individuals early.

Patients starting these medications should monitor symptoms closely. Apps like Shotlee can assist in tracking side effects, medication schedules, and progress, providing data to share with healthcare providers.

Expert Perspectives and Study Limitations

Andrea Ganna, a health data scientist at the University of Helsinki, noted, "I don't see this as something that clinicians are going to use to inform their practice." The genetic effects, though statistically significant, are small relative to overall variability.

Newsweek has previously covered Ozempic's broader benefits, such as improvements in mental health alongside its metabolic effects. This genetic study adds nuance without overshadowing the drug's proven track record.

What This Means for Patients Considering Ozempic

Who Might Benefit Most?

If you're obese or have type 2 diabetes, discuss Ozempic with your doctor, especially if family history suggests strong drug responses. While genetic testing isn't routine yet, services like 23andMe could offer insights. Compare options: Ozempic focuses on GLP-1, while tirzepatide's dual action might suit GIP-variant carriers—but weigh side effect risks.

Safety Considerations

Common side effects include nausea and vomiting, exacerbated by certain variants. Start low-dose, hydrate well, and eat smaller meals. Rare risks like pancreatitis or thyroid issues require monitoring. Always consult a physician before starting.

Practical Guidance

• Discuss genetics: Ask about pharmacogenomics testing.
• Track progress: Use journals or apps for weight, symptoms, and adherence.
• Lifestyle synergy: Pair with diet and exercise for amplified results.

Key Takeaways

• Specific GLP-1 genetic variants boost Ozempic weight loss by 0.76kg (one copy) or 1.5kg (two copies).
• GIP/GLP-1 variants increase nausea (57%), vomiting (36-83%) risks.
• Genetics explain some variability, but effects are small; holistic factors dominate.
• 23andMe study underscores precision medicine potential for GLP-1 drugs.

Conclusion: Toward Personalized GLP-1 Therapy

This 23andMe study illuminates why Ozempic works better for some, linking genetics to both enhanced weight loss and side effect profiles. While not yet changing daily practice, it empowers informed discussions with doctors. For patients, the message is clear: responses vary, but evidence-based use of semaglutide and tirzepatide offers real metabolic benefits. Stay tuned for more on GLP-1 genetics and metabolic health.